BioWorld

Ilab patents new PD-1/PD-L1 interaction inhibitors

BioWorld - Tuesday, March 11, 2025 Breaking News: BioWorld by Clarivate releases comprehensive 2024 year in review See today's BioWorld Science Home » Ilab patents new PD-1/PD-L1 interaction ...
ascopubs.org

Comparing clinical outcomes between PD-1 and PD-L1 inhibitors plus bevacizumab combined with hepatic arterial interventional therapies in unresectable hepatocellular carcinoma ...

Adjuvant therapy with donafenib plus anti–PD-1 antibody for patients (pts) with hepatocellular carcinoma (HCC) at high risk of recurrence after resection (PATH study). This is an ASCO Meeting Abstract ...
Business Wire

PD-1 x VEGF and PD-L1 x VEGF Bispecific Antibodies Market Research 2025: Ivonescimab has Set the Bar for Competitors - Business, Pipeline and Competitor Analysis ...

DUBLIN--(BUSINESS WIRE)--The "PD-1 x VEGF and PD-L1 x VEGF Bispecific Antibodies: A Business, Pipeline And Competitor Analysis From An Industry Perspective" report has been added to ResearchAndMarkets ...
News Medical

FDA accepted PD-L1 inhibitor durvalumab for the treatment of endometrial cancer

Durvalumab targets PD-L1, a key immune checkpoint. Normally, antigen-presenting cells (APCs) recognize cancer cell antigens and activate cytotoxic T cells, which travel to the tumor site for ...
FiercePharma

Checkpoint Therapeutics takes on Merck's mighty Keytruda with FDA approval for Unloxcyt in skin cancer

Another checkpoint inhibitor has entered the fray, as Checkpoint Therapeutics has passed the FDA’s checkpoint with its PD-L1 inhibitor cosibelimab. The FDA has approved cosibelimab under the brand ...
ascopubs.org

PD-1 inhibitors versus PD-L1 inhibitors in PD-L1–negative advanced non-small cell lung cancer: A meta-analysis of survival outcomes.

Predictive value of the triglyceride-glucose index for the efficacy of immunotherapy in patients with advanced NSCLC: A retrospective study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
The American Journal of Managed Care

Will Subcutaneous PD-1/PD-L1 Inhibitors Be a Game Changer?

With Bristol Myers Squibb (BMS) now rolling out the SC version of rival nivolumab (Opdivo Qvantig), the shift from 30-minute intravenous (IV) infusion to 5-minute SC injection could be one of the most ...
BioWorld

Aligos Therapeutics patents new inhibitors of PD-1, PD-L1 or PD-1/PD-L1 interaction

Aligos Therapeutics Inc. has disclosed programmed cell death 1 (PDCD1; PD-1; CD279) and/or PD-1 ligand 1 (PD-L1; CD274) and/or PD-1/PD-L1 interaction inhibitors reported to be useful for the treatment ...